DSpace logo

Use este identificador para citar ou linkar para este item: http://repositorioinstitucional.uea.edu.br//handle/riuea/5906
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorSouza, Paulo Henrique Rodrigues de-
dc.date.available2024-09-03-
dc.date.available2024-09-10T13:15:11Z-
dc.date.issued2024-02-26-
dc.identifier.urihttp://repositorioinstitucional.uea.edu.br//handle/riuea/5906-
dc.description.abstractParvovirus B19 (B19V) infects erythroid precursor cells, compromising red blood cell production. This can trigger severe anemia and other hematological diseases in susceptible patients. However, data on B19V epidemiology in patients with hematological diseases are scarce, especially in the Northern region of Brazil. The aim of this study was to estimate the prevalence of IgG and IgM antibodies against B19V, and to detect B19 DNA, in patients with hematological diseases undergoing treatment at a large blood center in the western Brazilian Amazon. Plasma samples from 421 patients were subjected to enzyme immunoassay for the detection of anti-B19V IgG and IgM antibodies. Subsequently, all samples underwent qPCR for viral DNA detection. B19V infection was prevalent in more than half of the study population (55.11%). Notably, women (PR: 1.62; 95% CI: 1.10–2.41; p = 0.016) and individuals aged 60 and above (PR: 7.72; 95% CI: 3.77–15.80; p = 0.016) were more susceptible to infection, as were patients with thrombophilia, lymphoma, and anemia, with thrombophilia showing the highest vulnerability (PR: 6.52; 95% CI: 1.78–23.88). Twelve e patients were positive for IgM anti-B19, and the presence of B19V DNA was confirmed in 2 patients (0.46%). Patients with hematological diseases, especially thrombophilia, are at increased risk of B19V infection, underscoring the importance of epidemiological surveillance and prevention strategies to improve clinical outcomes. of IgG and IgM antibodies against B19V, and the presence of B19 DNA, in patients with hematological diseases undergoing treatment at a major blood center in the western Brazilian Amazonpt_BR
dc.languageporpt_BR
dc.publisherUniversidade do Estado do Amazonaspt_BR
dc.rightsAcesso Abertopt_BR
dc.subjectDoenças hematológicaspt_BR
dc.subjectParvovírus B19pt_BR
dc.subjectEpidemiologiapt_BR
dc.subjectEritema infecciosopt_BR
dc.titlePrevalência da infecção por eritrovírus B19V em pacientes portadores de doenças hematológicaspt_BR
dc.title.alternativePrevalence of erythrovirus B19V infection in patients with hematological diseasespt_BR
dc.typeDissertaçãopt_BR
dc.date.accessioned2024-09-10T13:15:11Z-
dc.contributor.advisor-co1Barbosa, Anderson Nogueira-
dc.contributor.advisor-co1Latteshttp://lattes.cnpq.br/0743404839095493pt_BR
dc.contributor.advisor1Pontes, Gemilson Soares-
dc.contributor.advisor1Latteshttp://lattes.cnpq.br/9081671233815990pt_BR
dc.contributor.referee1Pontes, Gemilson Soares-
dc.contributor.referee1Latteshttp://lattes.cnpq.br/9081671233815990pt_BR
dc.contributor.referee2Tarragô, Andréa Monteiro-
dc.contributor.referee2Latteshttp://lattes.cnpq.br/4644326589690231pt_BR
dc.contributor.referee3Lima Junior, Raimundo Sousa-
dc.contributor.referee3Latteshttp://lattes.cnpq.br/2055426262014670pt_BR
dc.creator.Latteshttp://lattes.cnpq.br/1356457894955108pt_BR
dc.description.resumoO parvovírus B19 (B19V) infecta células precursoras eritroides, comprometendo a produção de hemácias. Isso pode desencadear anemia grave e outras doenças hematológicas em pacientes suscetíveis. No entanto, dados sobre a epidemiologia do B19V em pacientes com doenças hematológicas são escassos, especialmente na região Norte do Brasil. O objetivo deste estudo foi estimar a prevalência de anticorpos IgG e IgM contra o B19V e detectar o DNA B19 em pacientes com doenças hematológicas em tratamento em um hemocentro de grande porte na Amazônia ocidental brasileira. Amostras de plasma de 421 pacientes foram submetidas a ensaio imunoenzimático para detecção de anticorpos anti-B19V IgG e IgM. Posteriormente, todas as amostras foram submetidas à qPCR para detecção do DNA viral. A infecção pelo B19V foi prevalente em mais da metade da população estudada (55,11%). Notadamente, mulheres (RP: 1,62; 95% IC: 1,10–2,41; p = 0,016) e indivíduos com 60 anos ou mais (RP: 7,72; 95% IC: 3,77–15,80; p = 0,016) foram mais suscetíveis à infecção, assim como pacientes com trombofilia, linfoma e anemia, com trombofilia apresentando maior vulnerabilidade (RP: 6,52; 95% IC: 1,78–23,88). Doze pacientes foram positivos para IgM anti-B19, e a presença de DNA B19V foi confirmada em 2 pacientes (0,46%). Pacientes com doenças hematológicas, especialmente trombofilia, apresentam risco aumentado de infecção pelo B19V, ressaltando a importância de estratégias de vigilância epidemiológica e prevenção para melhorar os desfechos clínicos. de anticorpos IgG e IgM contra B19V e a presença de DNA B19 em pacientes com doenças hematológicas em tratamento em um importante hemocentro da Amazônia ocidental brasileirapt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.programPPGH -PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS APLICADAS À HEMATOLOGIApt_BR
dc.relation.references1. Cotmore SF, Agbandje-McKenna M, Canuti M, Chiorini JA, Eis-Hubinger A-M, Hughes J, Mietzsch M, Modha S, Ogliastro M, Pénzes JJ, et al. ICTV Virus Taxonomy Profile: Parvoviridae. Journal of General Virology (2019) 100:367–368. doi:10.1099/jgv.0.001212 2. Cotmore SF, Agbandje MM, Chiorini JA, Mukha D V., Pintel DJ, Qiu J, Soderlund VM, Tattersall P, Tijssen P, Gatherer D, et al. The family Parvoviridae. Arch Virol (2014) 159:1239–1247. doi:10.1007/s00705-013-1914-1 3. Kühl U, Lassner D, Pauschinger M, Gross UM, Seeberg B, Noutsias M, Poller W, Schultheiss HP. Prevalence of erythrovirus genotypes in the myocardium of patients with dilated cardiomyopathy. J Med Virol (2008) 80:1243–1251. doi:10.1002/jmv.21187 4. Blümel J, Rinckel LA, Lee DC, Roth NJ, Baylis SA. Inactivation and neutralization of parvovirus B19 Genotype 3. Transfusion (Paris) (2012) 52:1490–1497. doi:10.1111/j.1537-2995.2012.03573.x 5. Li X, Lin Z, Liu J, Tang Y, Yuan X, Li N, Lin Z, Chen Y, Liu A. Overall prevalence of human parvovirus B19 among blood donors in mainland China. Medicine (2020) 99:e19832. doi:10.1097/MD.0000000000019832 6. Raab U, Beckenlehner K, Lowin T, Niller HH, Doyle S, Modrow S. NS1 Protein of Parvovirus B19 Interacts Directly with DNA Sequences of the p6 Promoter and with the Cellular Transcription Factors Sp1/Sp3. Virology (2002) 293:86–93. doi:10.1006/viro.2001.1285 7. Allmon A, Deane K, Martin KL. Common Skin Rashes in Children. Am Fam Physician (2015) 92:211–6. 8. Faddy HM, Gorman EC, Hoad VC, Frentiu FD, Tozer S, Flower RLP. Seroprevalence of antibodies to primate erythroparvovirus 1 (B19V) in Australia. BMC Infect Dis (2018) 18:631. doi:10.1186/s12879-018-3525-7 9. Yaegashi N. Pathogenesis of Nonimmune Hydrops Fetalis Caused by Intrauterine B19 Infection. Tohoku J Exp Med (2000) 190:65–82. doi:10.1620/tjem.190.65 10. CNC Garcia R de, Leon LA. Human parvovirus B19: a review of clinical and epidemiological aspects in Brazil. Future Microbiol (2021) 16:37–50. doi:10.2217/fmb-2020-0123 11. Kostolansky S, Waymack JR. Erythema Infectiosum. (2023). 12. Sanabani S, Neto WK, Pereira J, Sabino EC. Sequence Variability of Human Erythroviruses Present in Bone Marrow of Brazilian Patients with Various Parvovirus B19-Related Hematological Symptoms. J Clin Microbiol (2006) 44:604–606. doi:10.1128/JCM.44.2.604-606.2006 46 13. Lindblom A, Heyman M, Gustafsson I, Norbeck O, Kaldensjo T, Vernby A, Henter J-I, Tolfvenstam T, Broliden K. Parvovirus B19 Infection in Children with Acute Lymphoblastic Leukemia is Associated with Cytopenia Resulting in Prolonged Interruptions of Chemotherapy. Clinical Infectious Diseases (2008) 46:528–536. doi:10.1086/526522 14. Heegaard ED, Jensen L, Hornsleth A, Schmiegelow K. The Role of Parvovirus B19 Infection in Childhood Acute Lymphoblastic Leukemia. Pediatr Hematol Oncol (1999) 16:329–334. doi:10.1080/088800199277155 15. Regaya F, Oussaief L, Bejaoui M, Karoui M, Zili M, Khelifa R. Parvovirus B19 infection in Tunisian patients with sickle-cell anemia and acute erythroblastopenia. BMC Infect Dis (2007) 7:123. doi:10.1186/1471-2334-7-123 16. Letalef M, Vanham G, Boukef K, Yacoub S, Muylle L, Mertens G. Higher prevalence of parvovirus B19 in Belgian as compared to Tunisian blood donors: Differential implications for prevention of transfusional transmission. Transfus Sci (1997) 18:523–530. doi:10.1016/S0955-3886(97)00049-0 17. Obeid OE. Molecular and serological assessment of parvovirus B19 infections among sickle cell anemia patients. The Journal of Infection in Developing Countries (2011) 5:535–539. doi:10.3855/jidc.1807 18. Jain P, Jain A, Prakash S, Khan DN, Singh DD, Kumar A, Moulik NR, Chandra T. Prevalence and genotypic characterization of human parvovirus B19 in children with hemato‐oncological disorders in North India. J Med Virol (2015) 87:303–309. doi:10.1002/jmv.24028 19. Garcia SO, Pereira J, Godoy CRT, Sanabani S, Kleine Neto W, Sabino EC. Hematologic Diseases Associated with Eritrovírus. Rev Bras Hematol Hemoter (2009) 31:285–290. doi:10.1590/S1516-84842009005000061 20. Furkan Demir B, Karahan Meteris A, Yirgin G, Comoglu M, Katipoglu B, Yılmaz N, Ates I. Parvovırus-induced thrombocytopenıa. Hematol Oncol Stem Cell Ther (2019) 12:226–227. doi:10.1016/j.hemonc.2018.05.003 21. Diallo D-A, Guindo A, Dorie A, Djibo N, Algiman E, Ouane O-D, Diakité A-A, Traoré F-F, Ag Baraika M, Dembélé A-K, et al. Human Parvovirus B19 Infection in Sickle Cell Anemia Patient in Mali: A Case-Control. Archives de Pédiatrie (2011) 18:962–965. doi:10.1016/j.arcped.2011.06.019 22. Kerr JR. Parvovirus B19 infection. European Journal of Clinical Microbiology & Infectious Diseases (1996) 15:10–29. doi:10.1007/BF01586181 23. Jain A, Jain P, Prakash S, Khan DN, Kumar A, Kant R. Prevalence of Parvovirus B19V in Hematological Malignancies and Chronic Anemia. The Indian Journal of Pediatrics (2018) 85:77–78. doi:10.1007/s12098-017-2428-8 24. Kerr JR. A review of blood diseases and cytopenias associated with human parvovirus B19 infection. Rev Med Virol (2015) 25:224–240. doi:10.1002/rmv.1839 25. Serjeant GR, Mason K, Topley JM, Serjeant BE, Pattison JR, Jones SE, Mohamed R. Outbreak of aplastic crises in sickle cell anaemia associated with parvovirus-like agent. The Lancet (1981) 318:595–597. doi:10.1016/S0140-6736(81)92739-2 26. Kelleher JF, Luban NLC, Mortimer PP, Kamimura T. Human serum “parvovirus”: A specific cause of aplastic crisis in children with hereditary spherocytosis. J Pediatr (1983) 102:720–722. doi:10.1016/S0022-3476(83)80243-1 27. Heegaard E, Rosthøj S, Petersen B, Nielsen S, Pedersen FK, Hornsleth A. Role of parvovirus B19 infection in childhood idiopathic thrombocytopenic purpura. Acta Paediatr (1999) 88:614–617. doi:10.1080/08035259950169251 47 28. van Elsacker-Niele A-MW, Weiland HT, Kroes ACM, Kappers-Klunne MC. Parvovirus B19 infection and idiopathic thrombocytopenic purpura*. Ann Hematol (1996) 72:141–144. doi:10.1007/s002770050152 29. Vilibic-Cavlek T, Tabain I, Kolaric B, Mihulja K, Blazevic L, Bogdanic M, Navolan D, Beader N, Mrzljak A. Parvovirus B19 in Croatia: A Large-Scale Seroprevalence Study. Medicina (B Aires) (2021) 57:1279. doi:10.3390/medicina57111279 30. Goral S, Yenicesu İ, Bozdayi G, Duyan Ç A, Altay K A. Parvovirus B19 seroprevalence in Turkish blood donors. Turk J Med Sci (2018) 48:956–960. doi:10.3906/sag-1802-150 31. Zhang L, Cai C, Pan F, Hong L, Luo X, Hu S, Xu J, Chen Z. Epidemiologic study of human parvovirus B19 infection in East China. J Med Virol (2016) 88:1113–1119. doi:10.1002/jmv.24459 32. Majumdar S, Bean CJ, De Staercke C, Bost J, Nickel R, Coates T, Campbell A, Thompson A. Parvovirus B19 infection in sickle cell disease: An analysis from the Centers for Disease Control haemoglobinopathy blood surveillance project. Transfusion Medicine (2020) 30:226–230. doi:10.1111/tme.12671 33. Urio F, George H, Tluway F, Nyambo TB, Mmbando BP, Makani J. Prevalence and Factors Associated with Human Parvovirus B19 Infection in Sickle Cell Patients Hospitalized in Tanzania. Mediterr J Hematol Infect Dis (2019) 11:e2019054. doi:10.4084/mjhid.2019.054 34. da Conceição Nunes J, de Araujo GV, Viana MT, Sarinho ESC. Association of atopic diseases and parvovirus B19 with acute lymphoblastic leukemia in childhood and adolescence in the northeast of Brazil. Int J Clin Oncol (2016) 21:989–995. doi:10.1007/s10147-016-0988-7 35. Slavov SN, Rodrigues ES, Sauvage V, Caro V, Diefenbach CF, Zimmermann AM, Covas DT, Laperche S, Kashima S. Parvovirus B19 seroprevalence, viral load, and genotype characterization in volunteer blood donors from southern Brazil. J Med Virol (2019) 91:1224–1231. doi:10.1002/jmv.25453 36. Slavov SN, Haddad SK, Silva-Pinto AC, Amarilla AA, Alfonso HL, Aquino VH, Covas DT. Molecular and phylogenetic analyses of human Parvovirus B19 isolated from Brazilian patients with sickle cell disease and β-thalassemia major and healthy blood donors. J Med Virol (2012) 84:1652–1665. doi:10.1002/jmv.23358 37. Freitas RB, Monteiro TAF, Silva FMG, Linhares AC. Association between human parvovirus B19 and arthropathy in Belém, Pará, north Brazil. Rev Inst Med Trop Sao Paulo (2002) 44:17–22. doi:10.1590/S0036-46652002000100004 38. VYSE AJ, ANDREWS NJ, HESKETH LM, PEBODY R. The burden of parvovirus B19 infection in women of childbearing age in England and Wales. Epidemiol Infect (2007) 135:1354–1362. doi:10.1017/S0950268807007856 39. Moosazadeh M, Alimohammadi M, Mousavi T. Seroprevalence and geographical distribution of parvovirus B19 antibodies in pregnant women: A-meta analysis. J Immunoassay Immunochem (2023) 44:103–116. doi:10.1080/15321819.2023.2167520 40. Bertoldi A, Colazo Salbetti MB, Rodríguez G, Tenaglia M, Hernández G, Alfaro J, Riberi MI, Olivera NL, Pedranti M, Isa MB, et al. Human parvovirus B19 infection in a pregnant patient resulting in severe hydrops, foetal death and persistent infection. Access Microbiol (2022) 4: doi:10.1099/acmi.0.000428 41. Ornoy A, Ergaz Z. Parvovirus B19 infection during pregnancy and risks to the fetus. Birth Defects Res (2017) 109:311–323. doi:10.1002/bdra.23588 48 42. Gonçalves G, Correia AM, Palminha P, Rebelo-Andrade H, Alves A. Outbreaks caused by parvovirus B19 in three Portuguese schools. Euro Surveill (2005) 10:121–4. 43. Rohrer C, Gartner B, Sauerbrei A, Bohm S, Hottentrager B, Raab U, Thierfelder W, Wutzler P, Modrow S. Seroprevalence of parvovirus B19 in the German population. Epidemiol Infect (2008) 136:1564–1575. doi:10.1017/S0950268807009958 44. Us T, Ozune L, Kasifoglu N, Akgun Y. The investigation of parvovirus B19 infection in patients with haematological disorders by using PCR and ELISA techniques. Brazilian Journal of Infectious Diseases (2007) 11:327–330. doi:10.1590/S1413-86702007000300006 45. da Costa AC, Bendit I, de Oliveira ACS, Kallas EG, Sabino EC, Sanabani SS. Investigation of human parvovirus B19 occurrence and genetic variability in different leukaemia entities. Clinical Microbiology and Infection (2013) 19:E31–E43. doi:10.1111/1469-0691.12058 46. Jitschin R, Peters O, Plentz A, Turowski P, Segerer H, Modrow S. Impact of parvovirus B19 infection on paediatric patients with haematological and/or oncological disorders. Clinical Microbiology and Infection (2011) 17:1336–1342. doi:10.1111/j.1469-0691.2010.03355.x 47. Hai An HP, Diem HT, Cuong NT. Parvovirus B19-Associated Anemia in Kidney Transplant Recipients: A Single-Center Experience. Transplant Proc (2019) 51:2693–2696. doi:10.1016/j.transproceed.2019.03.076 48. Goeijenbier M, van Wissen M, van de Weg C, Jong E, Gerdes VEA, Meijers JCM, Brandjes DPM, van Gorp ECM. Review: Viral infections and mechanisms of thrombosis and bleeding. J Med Virol (2012) 84:1680–1696. doi:10.1002/jmv.23354 49. Magro CM, Crowson AN, Dawood M, Nuovo GJ. Parvoviral infection of endothelial cells and its possible role in vasculitis and autoimmune diseases. J Rheumatol (2002) 29:1227–35. 50. beid Mohamed SO, Osman Mohamed EM, Ahmed Osman AA, Abdellatif Mohamedelmugadam FA, Abdalla Ibrahim GA. A Meta-Analysis on the Seroprevalence of Parvovirus B19 among Patients with Sickle Cell Disease. Biomed Res Int (2019) 2019: doi:10.1155/2019/2757450 51. Urio F, George H, Tluway F, Nyambo TB, Mmbando BP, Makani J. Prevalence and factors associated with human parvovirus B19 infection in sickle cell patients hospitalized in Tanzania. Mediterr J Hematol Infect Dis (2019) 11: doi:10.4084/mjhid.2019.054 52. Marano G, Vaglio S, Pupella S, Facco G, Calizzani G, Candura F, Liumbruno GM, Grazzini G. Human parvovirus B19 and blood product safety: A tale of twenty years of improvements. Blood Transfusion (2015) 13: doi:10.2450/2014.0174.14 53. Marco-Nacional-de-Hemovigilância-2022. 54. Agi E, Hojjatipour S, Namvar A, Bolhassani A. Impact of Blood Transfusion on the Prevalence of HHpgV-1, HPgV-1, and B19V among Iranian HCV-infected Patients with Hemophilia. J Pediatr Hematol Oncol (2020) doi:10.1097/MPH.0000000000001717 55. Healy K, Aulin LBS, Freij U, Ellerstad M, Brückle L, Hillmering H, Svae TE, Broliden K, Gustafsson R. Prevalence of Parvovirus B19 Viremia among German Blood Donations and the Relationship to ABO and Rhesus Blood Group Antigens. Journal of Infectious Diseases (2023) 227: doi:10.1093/infdis/jiac456 49 56. Dodd RY. B19: Benign or not? Transfusion (Paris) (2011) 51: doi:10.1111/j.1537-2995.2011.03274.xpt_BR
dc.publisher.initialsUEApt_BR
Aparece nas coleções:DISSERTAÇÃO - PPCAH Programa de Pós-Graduação em Ciências Aplicadas à Hematologia

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
Prevalência da infecção por eritrovírus B19V em pacientes portadores de doenças hematológicas.pdf3,84 MBAdobe PDFVisualizar/Abrir
Mostrar registro simples do item Visualizar estatísticas


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.